This article may rely excessively on sources too closely associated with the subject , potentially preventing the article from being verifiable and neutral.(June 2024) |
The Stanford Cancer Institute is an NCI-designated Cancer Center at Stanford University in Palo Alto, CA. It is one of eight comprehensive cancer centers in California.
The Stanford Cancer Institute leverages the scientific, technological, and human resources of Stanford University and Stanford Health Care to enhance the understanding of cancer. It facilitates the translation of research discoveries into improved prevention strategies, diagnostic methods, and more effective and safer therapies.
The Stanford Cancer Institute has more than 300 faculty members within the Stanford network. [1] Adult patients are treated at the Stanford Cancer Center. [2]
The Stanford Cancer Institute was founded in 2004 and first received NCI-designation as a clinical cancer center in 2007. In 2016, it received its comprehensive cancer center designation. [3] [1] In 2022, the Stanford Cancer Institute received its comprehensive cancer center designation renewal.
Stanford University was a founding member of the National Comprehensive Cancer Network in 1995. [4]
In 2016, a new center was created as part of the Parker Institute for Cancer Immunotherapy. Stanford received $10 million from the Parker Foundation. This is a $250 million joint venture with five other cancer centers across the country. [5]
In 2017, a donation by Jeffrey Rothschild established the Stanford Center for Cancer Cell Therapy, which supports research into the development of immunological based treatments for cancer. [6]
Roswell Park Comprehensive Cancer Center is a cancer research and treatment center located in Buffalo, New York. Founded by surgeon Roswell Park in 1898, the center was the first in the United States to specifically focus on cancer research. The center is usually called Roswell Park in short. The center, which conducts clinical research on cancer as well as the development new drugs, provides advanced treatment for all forms of adult and pediatric cancer, and serves as a member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center is as of 2019, the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center".
Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in Manhattan in New York City. It was founded in 1884 as the New York Cancer Hospital. MSKCC is one of 72 National Cancer Institute-designated Comprehensive Cancer Centers. It had already been renamed and relocated, to its present site, when the Sloan-Kettering Institute for Cancer Research was founded in 1945, and built adjacent to the hospital. The two medical entities formally coordinated their operations in 1960, and formally merged as a single entity in 1980. Its main campus is located at 1275 York Avenue between 67th and 68th Streets in Manhattan.
The Wistar Institute is an independent, nonprofit research institution in biomedical science with special focuses in oncology, immunology, infectious disease and vaccine research. Located on Spruce Street in Philadelphia’s University City neighborhood, Wistar was founded in 1892 as a nonprofit institution to focus on biomedical research and training.
NCI-designated Cancer Centers are a group of 72 cancer research institutions in the United States supported by the National Cancer Institute.
Moffitt Cancer Center & Research Institute is a nonprofit cancer treatment and research center located in Tampa, Florida. Established in 1981 by the Florida Legislature, the hospital opened in October 1986 on the University of South Florida's campus. Moffitt is one of two National Cancer Institute-designated Comprehensive Cancer Centers based in Florida. In 2021, U.S. News & World Report ranked Moffitt Cancer Center as a top 30 cancer hospital in the United States.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is a National Cancer Institute (NCI)-designated comprehensive cancer center located in Baltimore, Maryland.
The UPMC Hillman Cancer Center, previously the University of Pittsburgh Cancer Institute (UPCI), is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center located in the Hillman Cancer Center in the Shadyside neighborhood of Pittsburgh, adjacent to UPMC Shadyside. The only NCI-designated cancer center in Western Pennsylvania, Hillman is composed of collaborative academic and research efforts between the University of Pittsburgh, the University of Pittsburgh Medical Center (UPMC), and Carnegie Mellon University. Hillman provides clinical cancer care to some 74,000 patients treated at its facilities at both the Hillman Cancer Center location in the Shadyside neighborhood of Pittsburgh and at UPMC-affiliated sites throughout Pennsylvania, New York, Ohio, and overseas locations. Founded in 1984, Hillman became the youngest cancer center in history to achieve NCI-designation. As of 2007, Hillman had received nearly $200 million in funding from the National Cancer Institute, which ranks it as one of the top ten cancer research institutes.
The University of Chicago Medicine Comprehensive Cancer Center is a collaborative cancer research center based in Hyde Park, Chicago, United States. The Comprehensive Cancer Center is affiliated with the University of Chicago.
Larry Kwak is an American cancer researcher who works at City of Hope in Duarte, California and is the Director of the Toni Stephenson Lymphoma Center at City of Hope. Dr. Kwak formerly worked at the University of Texas MD Anderson Cancer Center. He was included on Time's list of 2010's most influential people.
The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is a cancer treatment, research and education institution with six locations in the St. Louis area. Siteman is the only cancer center in Missouri and within 240 miles of St. Louis to be designated a Comprehensive Cancer Center by the National Cancer Institute (NCI). Siteman is also the only area member of the National Comprehensive Cancer Network, a nonprofit alliance of 32 cancer centers dedicated to improving the quality and effectiveness of cancer care.
James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas.
Seattle Cancer Care Alliance (SCCA) is a cancer treatment and research center in Seattle, Washington. Established in 1998, this nonprofit provides clinical oncology care for patients treated at its three partner organizations: Fred Hutchinson Cancer Research Center, Seattle Children's and UW Medicine. Together, these four institutions form the Fred Hutch/University of Washington Cancer Consortium.
University of Virginia Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center affiliated with the University of Virginia School of Medicine and the UVA Health System.
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University is an NCI-Designated Comprehensive Cancer Center in Baltimore, MD. It was established in 1973 and received its NCI designation that same year as one of the first designated cancer centers in the country.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
Miram Merad is a French-Algerian professor in Cancer immunology and the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology and a member of the United States National Academy of Sciences and the National Academy of Medicine.
Crystal L. Mackall is an American physician and immunologist. She is currently the Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine at Stanford University. She is the founding director of the Stanford Center for Cancer Cell Therapy.
Suzanne Louise Topalian is an American surgical oncologist. She is the Bloomberg-Kimmel Professor of Cancer Immunotherapy in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine. In this role, she studies human anti-tumor immunity.
Nilofer Saba Azad is an American oncologist and physician-scientist specialized in gastrointestinal, colorectal, cholangiocarcinoma, and pancreaticobiliary cancers. She is a professor at the Johns Hopkins School of Medicine and oversees clinical trials at the Sidney Kimmel Comprehensive Cancer Center.
Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics.